Phase 2 Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been confirmed through genetic testing to carry the Huntington's disease (HD) gene, with a result showing 36 or more CAG repeats in the HTT gene.
- You have been diagnosed with HD and show clear signs of the disease on a standard neurological examination.
- Your HD is in an early or middle stage (Shoulson-Fahn stage 1–3) and you still have some level of daily functioning (TFC score above 2).
- You are able to walk indoors on your own or with the help of a walking aid (such as a cane or walker).
- You are able to write and complete pen-and-paper tests and questionnaires included in the study.
- You are able to attend study visits (on your own or with help from a family member, friend, or carer) and take part in scheduled phone calls.
- You are comfortable having blood drawn.
- If you are a woman who could become pregnant, you are willing to use a highly effective form of birth control throughout the study.
- You are able to understand the study and give your own signed consent to take part.
Who may not be able to join:
- You have another significant neurological or psychiatric condition, such as a psychotic disorder, brain tumour, or inflammatory brain disease.
- You have attempted suicide or had active thoughts of suicide within the past 12 months.
- You have had a problem with alcohol or drug misuse or dependence (not including tobacco) in the 12 months before the start of the study.
- You have had cancer in the past 5 years (except for certain successfully treated minor skin cancers or a specific type of cervical pre-cancer), or you had cancer more than 5 years ago that still carries a meaningful risk of coming back.
- You have been diagnosed with significant heart disease (coronary artery disease) or significant blood vessel disease affecting the brain.
- You have a high cardiovascular (heart and circulation) risk based on a specific risk assessment tool that takes into account factors like smoking, blood pressure, cholesterol, and family history (confirm with trial site).
- You have any other medical condition that the study doctor believes could make it unsafe for you to participate or could affect the study results.
- You have taken any form of vitamin B3 (niacin) supplements within the past 3 months or plan to take them during the study.
- You have a major surgery planned during the study period that could affect your physical or mental assessments (for example, joint replacement or spinal surgery).
- You have received or are receiving electroconvulsive therapy (ECT).
- You are taking a medication with known serious side effects that the study doctor believes could affect your safety or the study results.
- You have previously received any gene therapy for the treatment of HD.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lasse Pihlstrøm, PhD, Oslo University Hospital
Phone: +47 95143795
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in the composite Unified Huntington's Disease Rating Scale at 730 days
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.